Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NT-112 |
Trade Name | |
Synonyms | NT112|NT 112 |
Drug Descriptions |
NT-112 comprises autologous T lymphocytes engineered to express an HLA-C*08:02-restricted T-cell receptor (TCR) targeting KRAS G12D, which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing KRAS G12D and inhibits tumor growth (Clin Oncol 42, 2024 (suppl 16; e14533, NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C204099 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
NT-112 | NT-112 | 0 | 1 |